Delivering next-generation treatments for back of the eye disorders, with focus on diabetic eye disease

Shareholder Information

Oxurion is listed on Euronext Brussels under the symbol OXUR.

As of 31 December 2018, Oxurion has a total number of 38,291,950 outstanding shares and a total number of 1,814,750 warrants, of which 1,139,750 are accepted unexercised and 675,000 are to be assigned.

KBC Bank is acting as the paying agent. The paying agent will not charge shareholders with respect to payments of dividends, the exercise of subscription rights and other events concerning Oxurion shares. Shareholders should inform themselves about the amounts that other financial intermediaries may charge in connection with paying agency services.

View Shareholders History of Capital


Extraordinary and Annual Shareholders Meeting 2019
  • Convocation of the extraordinary shareholders' meeting on December 13, 2019 – view document
  • Proxy form for the extraordinary shareholders' meeting – view document
  • Shareholders' rights pursuant to art.533ter and 540 BCC – view document
  • Special Board Report in accordance with Article 7:228 of the Belgian Companies and Association Code – view document
  • Proxies for the Annual General Shareholders' meeting on May 7, 2019 - (see attached)
  • Minutes of the Annual General Shareholders' meeting on May 7, 2019 - (see attached)
  • Convocation of Extraordinary Annual Shareholders' Meeting on May 24, 2019 - (see attached)
  • Proxy form for the Extraordinary Annual Shareholders' Meeting on May 24, 2019 - (see attached)
  • Convocation of Extraordinary and Annual Shareholders' Meeting on May 7, 2019 – (see attached)
  • Proxy form for the Extraordinary and Annual Shareholders' Meeting – (see attached)
  • Shareholders' rights pursuant to art.533ter and 540 BCC – (see attached)
  • Proposed Amendments - Articles of Association Oxurion NV de dato November 8, 2018 (see attached)      

Archive